AtriCure Reports First Quarter 2022 Financial Results

Rhea-AI Summary

AtriCure, Inc. (Nasdaq: ATRC) reported its first quarter 2022 financial results, showcasing a 25.8% revenue increase to $74.6 million compared to Q1 2021. U.S. revenue rose by 23.8% to $62.3 million, driven by strong sales in cryoSPHERE® probes and AtriClip® Flex-V devices. International revenue also surged by 37.2% to $12.3 million. Despite a net loss of $14.2 million, the company maintains a positive outlook with projected full-year revenue of $318 million to $330 million, anticipating 16% to 20% growth for 2022.

Positive

• Revenue increased by 25.8% year-over-year to $74.6 million.
• U.S. revenue grew by 23.8%, primarily from key products.
• International revenue climbed by 37.2%, indicating strong global demand.
• Management projects full-year revenue growth of 16% to 20% for 2022.

Negative

• Loss from operations was $14.2 million, although it improved from $15.9 million in Q1 2021.
• Adjusted EBITDA was negative at $4.2 million for the quarter.

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2022 financial results.

“Our team delivered exceptional first quarter performance, with broad-based growth across all key products,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “With EPi-Sense^® adoption building, continued expansion of our Cryo Nerve Block team, and the full commercial launch of our EnCompass^® clamp now underway, we are confident in the strength of our portfolio today while we invest in additional long-term drivers for sustained growth.”

First Quarter 2022 Financial Results

Revenue for the first quarter 2022 was $74.6 million, an increase of 25.8% (an increase of 26.7% on a constant currency basis) over first quarter 2021 revenue. U.S. revenue was $62.3 million, an increase of $12.0 million or 23.8%, compared to first quarter 2021 revenue. U.S. revenue growth was driven by sales across key product lines, notably the cryoSPHERE^® probe and AtriClip^® Flex-V devices. International revenue increased $3.3 million or 37.2% (an increase of 43.1% on a constant currency basis) to $12.3 million, reflecting growth in most major markets and across product lines. On a sequential basis, worldwide revenue for the first quarter 2022 increased approximately 1.9% over fourth quarter 2021.

Gross profit for the first quarter 2022 was $55.6 million compared to $44.5 million for the first quarter 2021. Gross margin was 74.5% and 75.1% for the first quarters 2022 and 2021 respectively, reflecting geographic and product mix, as well as increasing costs. Loss from operations for the first quarter 2022 was $14.2 million, compared to $15.9 million for the first quarter 2021. Basic and diluted net loss per share was $0.33 for the first quarter 2022, compared to $0.38 for the first quarter 2021.

Adjusted EBITDA was negative for the first quarter 2022 at $4.2 million, compared to negative $4.7 million for first quarter of 2021. Adjusted loss per share for the first quarter 2022 was $0.33 compared to $0.32 for the first quarter 2021.

Constant currency revenue, adjusted EBITDA and adjusted loss per share are non-GAAP measures. We discuss these non-GAAP measures and provide reconciliations to GAAP measures later in this release.

2022 Financial Guidance

Full year 2022 revenue is projected to be approximately $318 million to $330 million, reflecting growth of approximately 16% to 20% over full year 2021. Management continues to expect full year 2022 adjusted EBITDA to be a loss of approximately $2 million to $4 million, and the full year 2022 adjusted loss per share of approximately $1.07 to $1.12.

Conference Call

AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, May 3, 2022 to discuss its first quarter 2022 financial results. The call may be accessed through an operator by calling (844) 884-9951 for domestic callers and (661) 378-9661 for international callers using conference ID number 6061899. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at ir.atricure.com. A replay of the presentation will be available for 90 days following the presentation.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

Forward-Looking Statements

This press release contains “forward-looking statements”– that is, statements related to future events that by their nature address matters that are uncertain. This press release also includes forward-looking projected financial information that is based on current estimates and forecasts. Actual results could differ materially. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, visit http://www.atricure.com/forward-looking-statements as well as our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q which contain risk factors. Except where otherwise noted, the information contained in this release and the related attachment is as of May 3, 2022. We assume no obligation to update any forward-looking statements contained in this release and the related attachment as a result of new information or future events or developments, except as may be required by law.

Use of Non-GAAP Financial Measures

To supplement AtriCure’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, AtriCure provides certain non-GAAP financial measures in this release as supplemental financial metrics.

Revenue reported on a constant currency basis is a non-GAAP measure, calculated by applying previous period foreign currency exchange rates, which are determined by the average daily Euro to Dollar exchange rate, to each of the comparable periods. Management analyzes revenue on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on revenue, the Company believes that evaluating growth in revenue on a constant currency basis provides an additional and meaningful assessment of revenue to both management and investors.

Adjusted EBITDA is calculated as net income (loss) before other income/expense (including interest), income tax expense, depreciation and amortization expense, share-based compensation expense, acquisition costs, legal settlement costs, impairment of intangible asset and change in fair value of contingent consideration liabilities.

Management believes in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. The excluded items vary in frequency and/or impact on our continuing results of operations and management believes that the excluded items are typically not reflective of our ongoing core business operations and financial condition. Further, management uses adjusted EBITDA for both strategic and annual operating planning. A reconciliation of adjusted EBITDA reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of Non-GAAP Adjusted Loss (Adjusted EBITDA)” later in this release.

Adjusted income (loss) per share is a non-GAAP measure which calculates the net income (loss) per share before non-cash adjustments in fair value of contingent consideration liabilities, impairment of intangible asset and legal settlement costs. A reconciliation of adjusted income (loss) per share reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of Non-GAAP Adjusted Loss Per Share” later in this release.

The non-GAAP financial measures used by AtriCure may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for AtriCure’s financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financials measures included in this press release, and not to rely on any single financial measure to evaluate our business.

ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In Thousands, Except Per Share Amounts) (Unaudited)
	Three Months Ended March 31,
	2022				2021
United States Revenue:
Open ablation	$	18,974			$	17,439
Minimally invasive ablation		8,615				8,385
Pain management		8,014				3,898
Total ablation		35,603				29,722
Appendage management		26,669				20,587
Total United States		62,272				50,309
International Revenue:
Open ablation		6,492				4,434
Minimally invasive ablation		1,533				1,274
Pain management		140				—
Total ablation		8,165				5,708
Appendage management		4,139				3,258
Total International		12,304				8,966
Total revenue		74,576				59,275
Cost of revenue		18,981				14,735
Gross profit		55,595				44,540
Operating expenses:
Research and development expenses		13,629				11,217
Selling, general and administrative expenses		56,116				49,208
Total operating expenses		69,745				60,425
Loss from operations		(14,150	)			(15,885	)
Other expense, net		(977	)			(1,001	)
Loss before income tax expense		(15,127	)			(16,886	)
Income tax expense		56				31
Net loss	$	(15,183	)		$	(16,917	)
Basic and diluted net loss per share	$	(0.33	)		$	(0.38	)
Weighted average shares used in computing net loss per share:
Basic and diluted		45,528				44,632

ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In Thousands) (Unaudited)
	March 31, 2022				December 31, 2021
Assets
Current assets:
Cash, cash equivalents, and short-term investments	$	111,397			$	119,090
Accounts receivable, net		40,878				33,021
Inventories		40,762				38,964
Prepaid and other current assets		6,570				5,001
Total current assets		199,607				196,076
Long-term investments		70,514				104,338
Property and equipment, net		32,867				31,409
Operating lease right-of-use assets		4,509				4,761
Goodwill and intangible assets, net		276,801				277,773
Other noncurrent assets		685				955
Total assets	$	584,983			$	615,312
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued liabilities	$	45,615			$	54,689
Other current liabilities and current maturities of leases		1,760				1,756
Total current liabilities		47,375				56,445
Long-term debt		59,848				59,741
Finance lease liabilities		9,845				10,082
Operating lease liabilities		3,865				4,068
Other noncurrent liabilities		1,225				1,220
Total liabilities		122,158				131,556
Stockholders' equity:
Common stock		46				46
Additional paid-in capital		761,580				764,811
Accumulated other comprehensive loss		(3,465	)			(948	)
Accumulated deficit		(295,336	)			(280,153	)
Total stockholders' equity		462,825				483,756
Total liabilities and stockholders' equity	$	584,983			$	615,312

ATRICURE, INC. AND SUBSIDIARIES RECONCILIATION OF GAAP RESULTS TO NON-GAAP RESULTS (In Thousands) (Unaudited)
Reconciliation of Non-GAAP Adjusted Loss (Adjusted EBITDA)
	Three Months Ended March 31,
	2022				2021
Net loss, as reported	$	(15,183	)		$	(16,917	)
Income tax expense		56				31
Other expense, net		977				1,001
Depreciation and amortization expense		2,867				2,122
Share-based compensation expense		7,049				6,604
Change in fair value of contingent consideration		—				2,500
Non-GAAP adjusted loss (adjusted EBITDA)	$	(4,234	)		$	(4,659	)



Reconciliation of Non-GAAP Adjusted Loss Per Share
	Three Months Ended March 31,
	2022				2021
Net loss, as reported	$	(15,183	)		$	(16,917	)
Change in fair value of contingent consideration		—				2,500
Non-GAAP adjusted net loss	$	(15,183	)		$	(14,417	)
Basic and diluted adjusted net loss per share	$	(0.33	)		$	(0.32	)
Weighted average shares used in computing adjusted net loss per share
Basic and diluted		45,528				44,632

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005997/en/

Angie Wirick

AtriCure, Inc.

Chief Financial Officer

(513) 755-5334

awirick@atricure.com

Lynn Lewis

Gilmartin Group

Investor Relations

(415) 937-5402

lynn@gilmartinir.com

Source: AtriCure, Inc.

FAQ

What were AtriCure's first quarter 2022 revenue results?

AtriCure reported first quarter 2022 revenue of $74.6 million, a 25.8% increase from Q1 2021.

How did AtriCure perform in the U.S. market during Q1 2022?

U.S. revenue for Q1 2022 was $62.3 million, reflecting a 23.8% growth compared to the same quarter in 2021.

What is AtriCure's financial outlook for 2022?

AtriCure projects full-year 2022 revenue between $318 million to $330 million, indicating a growth rate of 16% to 20%.

What was AtriCure's net loss for the first quarter of 2022?

The net loss for Q1 2022 was $14.2 million, an improvement from a $15.9 million loss in Q1 2021.

What were the adjusted EBITDA results for AtriCure in Q1 2022?

Adjusted EBITDA for the first quarter of 2022 was negative at $4.2 million.